‘Booster shots, pediatric jabs to keep vaccine demand high,’ says Emcure MD

Phase II, III trials underway for COVID vaccine: Satish Mehta

Emcure Pharmaceuticals Ltd is seeing new growth opportunities in biologics and vaccines which it intends to introduce in various emerging markets. Being the first Indian company to have developed an indigenous mRNA platform, it is in the process of developing an mRNA COVID-19 vaccine via its subsidiary Gennova Biopharmaceuticals Ltd., for which it has received funding from the Government of India. Three other vaccines on its mRNA platform are in development stages, targeted at Zoster, Zika and Rabies, said , MD and CEO.

In August, the Vaccine Subject Expert Committee (SEC) reviewed the interim Phase I data, and found that our vaccine candidate HGCO19 was safe, tolerable, and immunogenic in the participants of the study.

The Drug Controller General of India then approved Phase II and Phase III study protocols for the vaccine, which are currently underway in India.